Table 2.
Treatment Delivery
| Characteristics | N = 17 |
|---|---|
| Total no. of treatment cycles | 3 [2, 5] |
| Cycles received, n (%) | |
| 1 | 4 (23.5) |
| 2 | 4 (23.5) |
| 3 | 2 (11.8) |
| ≥4 | 7 (41.2) |
| Reason for discontinuation of study treatment, n (%) | |
| Disease progression | 5 (29.4) |
| Pneumonitis | 5 (29.4) |
| Termination of this clinical trial | 6 (35.2)a |
| Violation of eligibility criteria | 1 (5.9) |
a
Five of the six patients, who were on treatment at the time the trial was terminated, continued to receive atezolizumab as a real clinical treatment outside of this trial because they understood the risks and still wanted to.